Safety of Immune Checkpoint Inhibitors With Nephrectomy in mRCC
A pilot study evaluated cytoreductive surgery combined with immune checkpoint therapy in patients with metastatic renal cell carcinoma.
Promising CAR T-Cell Agent for ALL Enters Phase II With Revised AE Management Protocol
A phase I study of a CAR T-cell therapy showed success in refining cell dosing and adverse event management protocols in patients with relapsed/refractory ALL.
2 Clarke Drive Cranbury, NJ 08512